Related Experiment Video
Updated: Oct 26, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers
Vakul Mohanty1, Fang Wang1, Gordon B Mills2
1Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Uncoupling of mRNA expression from copy number (UECN) might be a strategy for cancer cells to a tolerate high degree of aneuploidy. To test the extent and role of UECN across cancers, we perform integrative multiomic analysis of The Cancer Genome Atlas (TCGA) dataset, encompassing ∼5,000 individual tumors. We find UECN is common in cancers and is associated with increased oncogenic signaling, proliferation, and immune suppression. UECN appears to be orchestrated by complex regulatory changes, with transcription factors (TFs) playing a prominent role. To further dissect the regulatory mechanisms, we develop a systems-biology approach to identify candidate TFs, which could serve as targets to disrupt UECN and reduce tumor fitness. Applying our approach to TCGA data, we identify 21 putative targets, 42.8% of which are validated by independent sources. Together, our study indicates that UECN is likely an important mechanism in development of aneuploid tumors and might be therapeutically targetable.
Insights
Uncoupling of mRNA expression from copy number (UECN) helps cancer cells survive high aneuploidy. This study reveals UECN is common, linked to tumor growth and immune evasion, and offers potential therapeutic targets.
Area of Science:
- Cancer Biology
- Genomics
- Systems Biology
Background:
- Aneuploidy, an abnormal chromosome number, is common in cancer.
- Uncoupling of mRNA expression from copy number (UECN) may allow cancer cells to tolerate aneuploidy.
Purpose of the Study:
- To investigate the prevalence and role of UECN across various cancer types.
- To identify regulatory mechanisms and potential therapeutic targets for UECN.
Main Methods:
- Integrative multiomic analysis of The Cancer Genome Atlas (TCGA) dataset (∼5,000 tumors).
- Development of a systems-biology approach to identify candidate transcription factors (TFs).
Main Results:
- UECN is a common phenomenon in cancer.
- UECN correlates with increased oncogenic signaling, proliferation, and immune suppression.
- Identified 21 putative TF targets, with 42.8% validated by independent sources.
Conclusions:
- UECN is a significant mechanism in the development of aneuploid tumors.
- Targeting TFs involved in UECN may offer a therapeutic strategy to reduce tumor fitness.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Nondisjunction
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

